<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323076</url>
  </required_header>
  <id_info>
    <org_study_id>SP-14-0050/DX-FAZ-001/22390</org_study_id>
    <nct_id>NCT00323076</nct_id>
  </id_info>
  <brief_title>Imaging Study in Patients With Cancer of the Head &amp; Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours</brief_title>
  <official_title>A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head &amp; Neck, Small Cell and Non-Small Cell Carcinoma of the Lung, Lymphoma, Glioblastoma Multiforme, Neuroendocrine Tumours or Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron
      emitting radiolabeled tracer molecules to visualize biological activity. The presence of
      hypoxia (low oxygen) is associated with poor prognosis in a variety of tumour types and
      treatment strategies targeting hypoxic cells have been developed. The PET tracer [18]F-FAZA
      can identify hypoxic areas, and changes in uptake during treatment may predict tumour
      response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed clinical trial will be a Phase I/II imaging, open label, single site study. In
      Phase I, one 18F-FAZA PET scan will be conducted in patients with known squamous cell
      carcinoma of the Head &amp; Neck, SCLC, NSCLC, lymphoma, GGM, neuroendocrine tumours or renal
      cell carcinoma. In Phase II, three 18F-FAZA PET scans will be done on patients with the above
      tumours as follows: one pre-treatment, one mid course and one post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2004</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: demonstrate the safety of 18F-FAZA manufactured at the Edmonton Radiopharmaceutical Centre/Edmonton PET Centre. Phase II: determine the general biodistribution pattern of18F-FAZA.</measure>
    <time_frame>Phase I: 2 years, Phase II: 5 years</time_frame>
    <description>Phase I: Pre-injection and post-imaging vital signs, blood haematology and blood chemistry, adverse event collection.
Phase II: The location and relative uptake of normal and abnormal 18F-FAZA biodistribution patterns will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the relative tumour uptake of 18F-FAZA</measure>
    <time_frame>5 years</time_frame>
    <description>Measure relative uptake scores (RUS) and tumour to background ratios (T/B) and correlate this uptake to disease progression, disease-free survival, overall survival and response to treatment over 12 months of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirm the safety of 18F-FAZA manufactured at the Edmonton Radiopharmaceutical Centre/Edmonton PET Centre</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse event collection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Neuroendocrine Tumours</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-FAZA PET Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FAZA PET Imaging</intervention_name>
    <description>Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.
Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female greater than or equal to 16 years of age.

          -  If female of child-bearing potential and outside of the window of 10 days since the
             first day of the last menstrual period, a negative pregnancy test is required.

          -  Patients with known primary or suspected metastatic squamous cell carcinoma of the
             head and neck, non-small cell or small cell carcinoma of the lung, lymphoma, GBM
             (greater than or equal to 3 glioma), neuroendocrine tumours, or renal cell carcinoma
             with at least one lesion &gt;1 cm in diameter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander J.B. McEwan, MB, MSc, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lai Schrader</last_name>
    <phone>780-432-8464</phone>
    <email>Lai.Schrader@albertahealthservices.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Landon</last_name>
    <phone>780-432-8751</phone>
    <email>Margaret.Landon@albertahealthservices.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Mercer, BSc, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Hudson, BMedSc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.edmontonpetcentre.com</url>
  </link>
  <reference>
    <citation>Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1565-73. doi: 10.1007/s00259-009-1154-5. Epub 2009 May 9.</citation>
    <PMID>19430784</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

